Bladder cancer drugs under the microscope: do they work in everyday practice?
NCT ID NCT07207928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study followed 35 adults with advanced urothelial (bladder) cancer who had stable disease after initial chemotherapy. They received either Avelumab as first-line maintenance therapy or Pembrolizumab as second-line therapy. Researchers tracked how long the cancer stayed under control, side effects, and costs over 12 months, with up to 10 years of past data. The goal is to see how these drugs perform in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Avelumab and Pembrolizumab
- What this could lead to
- If successful, this study could provide real-world evidence on the effectiveness and cost of these immunotherapies, helping doctors make better treatment decisions for advanced bladder cancer.
- What could go wrong
- This is a small observational study (35 people) that looks back at past data and follows patients for only 12 months. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera Universitaria Integrata di Verona
Verona, Verona, 37134, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral drug targets Cancer's growth engine in advanced tumours
- Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
- New drug combo aims to tackle Hard-to-Treat HER2 cancers
- New drug YH32364 targets Hard-to-Treat cancers in first human trial
- New drug cocktail aims to outperform chemo for advanced bladder cancer
- New drug combo may help bladder cancer patients keep their bladder